A citation-based method for searching scientific literature

Mengsi Lin, Xinyi Hu, Shiyi Chang, Yan Chang, Wenjun Bian, Ruikun Hu, Jing Wang, Qingwen Zhu, Jiaying Qiu. Evid Based Complement Alternat Med 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



DNase II: genes, enzymes and function.
Cory J Evans, Renato J Aguilera. Gene 2003
160
100

U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP.
Timothy A Vickers, Mahyar Sabripour, Stanley T Crooke. Nucleic Acids Res 2011
15
100

Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
H Sands, L J Gorey-Feret, A J Cocuzza, F W Hobbs, D Chidester, G L Trainor. Mol Pharmacol 1994
243
100

Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.
Yoshitsugu Aoki, Matthew J A Wood. J Neuromuscul Dis 2021
2
100

Safety, Tissue Distribution, and Metabolism of LNA-Containing Antisense Oligonucleotides in Rats.
Fernando Romero-Palomo, Matthias Festag, Barbara Lenz, Simone Schadt, Andreas Brink, Anja Kipar, Bernd Steinhuber, Christophe Husser, Erich Koller, Sabine Sewing,[...]. Toxicol Pathol 2021
1
100

Preclinical evaluation of juvenile toxicity.
Paul C Barrow, Stéphane Barbellion, Jeanne Stadler. Methods Mol Biol 2011
21
100

Systemic administration of PRO051 in Duchenne's muscular dystrophy.
Nathalie M Goemans, Mar Tulinius, Johanna T van den Akker, Brigitte E Burm, Peter F Ekhart, Niki Heuvelmans, Tjadine Holling, Anneke A Janson, Gerard J Platenburg, Jessica A Sipkens,[...]. N Engl J Med 2011
508
100


Clinical Pharmacology and Pharmacometrics to Better Understand Physiological Changes During Pregnancy and Neonatal Life.
Tamara van Donge, Katrina Evers, Gilbert Koch, John van den Anker, Marc Pfister. Handb Exp Pharmacol 2020
6
100

Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
Suzan M Hammond, Annemieke Aartsma-Rus, Sandra Alves, Sven E Borgos, Ronald A M Buijsen, Rob W J Collin, Giuseppina Covello, Michela A Denti, Lourdes R Desviat, Lucía Echevarría,[...]. EMBO Mol Med 2021
20
100



Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9.
Eveline P van Poelgeest, Reinout M Swart, Michiel G H Betjes, Matthijs Moerland, Jan J Weening, Yann Tessier, Michael R Hodges, Arthur A Levin, Jacobus Burggraaf. Am J Kidney Dis 2013
58
100

Comprehensive Analysis of Transcript and Protein Relative Abundance During Blood Stages of Plasmodium falciparum Infection.
Claire Kamaliddin, Emilie Guillochon, Virginie Salnot, David Rombaut, Stéphanie Huguet, François Guillonneau, Sandrine Houzé, Michel Cot, Philippe Deloron, Nicolas Argy,[...]. J Proteome Res 2021
2
100


Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
Rosie Z Yu, Kristina M Lemonidis, Mark J Graham, John E Matson, Rosanne M Crooke, Diane L Tribble, Mark K Wedel, Arthur A Levin, Richard S Geary. Biochem Pharmacol 2009
80
100


Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
Michael E Østergaard, Cheryl L De Hoyos, W Brad Wan, Wen Shen, Audrey Low, Andres Berdeja, Guillermo Vasquez, Susan Murray, Michael T Migawa, Xue-Hai Liang,[...]. Nucleic Acids Res 2020
25
100

The powerful world of antisense oligonucleotides: From bench to bedside.
Anaïs M Quemener, Laura Bachelot, Anne Forestier, Emmanuelle Donnou-Fournet, David Gilot, Marie-Dominique Galibert. Wiley Interdiscip Rev RNA 2020
47
100

Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.
Eveline P van Poelgeest, Michael R Hodges, Matthijs Moerland, Yann Tessier, Arthur A Levin, Robert Persson, Marie W Lindholm, Kamille Dumong Erichsen, Henrik Ørum, Adam F Cohen,[...]. Br J Clin Pharmacol 2015
56
100

Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
Michael Lykke Hvam, Yunpeng Cai, Frederik Dagnæs-Hansen, Jesper Sejrup Nielsen, Jesper Wengel, Jørgen Kjems, Kenneth A Howard. Mol Ther 2017
22
100


Genetic therapies for inherited neuromuscular disorders.
Mariacristina Scoto, Richard Finkel, Eugenio Mercuri, Francesco Muntoni. Lancet Child Adolesc Health 2018
20
100

Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
Paul J White, Frank Anastasopoulos, Colin W Pouton, Ben J Boyd. Expert Rev Mol Med 2009
38
100

The RETHINK project on minipigs in the toxicity testing of new medicines and chemicals: conclusions and recommendations.
Roy Forster, Gerd Bode, Lars Ellegaard, Jan-Willem van der Laan. J Pharmacol Toxicol Methods 2010
43
100

The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development.
Miriam Ayuso, Laura Buyssens, Marina Stroe, Allan Valenzuela, Karel Allegaert, Anne Smits, Pieter Annaert, Antonius Mulder, Sebastien Carpentier, Chris Van Ginneken,[...]. Pharmaceutics 2020
4
100

Selection of reference genes for gene expression studies in pig tissues using SYBR green qPCR.
Ann-Britt Nygard, Claus B Jørgensen, Susanna Cirera, Merete Fredholm. BMC Mol Biol 2007
327
100


Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine.
Henrike Bruckmueller, Paul Martin, Meike Kähler, Sierk Haenisch, Marek Ostrowski, Marek Drozdzik, Werner Siegmund, Ingolf Cascorbi, Stefan Oswald. Mol Pharm 2017
21
100

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.
Yifat S Oren, Michal Irony-Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Yao Li, Jeong Hong, Efrat Ozeri-Galai, Aurélie Hatton, Chen Leibson,[...]. J Cyst Fibros 2021
3
100


Gapmer Antisense Oligonucleotides Targeting 5S Ribosomal RNA Can Reduce Mature 5S Ribosomal RNA by Two Mechanisms.
Adam J Pollak, Justin H Hickman, Xue-Hai Liang, Stanley T Crooke. Nucleic Acid Ther 2020
5
100

New roles for the major human 3'-5' exonuclease TREX1 in human disease.
David Kavanagh, Dirk Spitzer, Parul H Kothari, Aisha Shaikh, M Kathryn Liszewski, Anna Richards, John P Atkinson. Cell Cycle 2008
88
100

Paediatric pharmacokinetics and drug doses.
Kate O'Hara. Aust Prescr 2016
15
100

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates.
Marie W Lindholm, Joacim Elmén, Niels Fisker, Henrik F Hansen, Robert Persson, Marianne R Møller, Christoph Rosenbohm, Henrik Ørum, Ellen M Straarup, Troels Koch. Mol Ther 2012
108
100

Is it useful to use several "omics" for obtaining valuable results?
Magdalena Zapalska-Sozoniuk, Lukasz Chrobak, Krzysztof Kowalczyk, Marta Kankofer. Mol Biol Rep 2019
11
100

Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass Spectrometry.
Jaeah Kim, Babak Basiri, Chopie Hassan, Carine Punt, Erik van der Hage, Cathaline den Besten, Michael G Bartlett. Mol Ther Nucleic Acids 2019
15
100

Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development.
Shalini Andersson, Madeleine Antonsson, Marie Elebring, Rasmus Jansson-Löfmark, Lars Weidolf. Drug Discov Today 2018
23
100

Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins.
Michael T Migawa, Wen Shen, W Brad Wan, Guillermo Vasquez, Michael E Oestergaard, Audrey Low, Cheryl L De Hoyos, Ruchi Gupta, Susan Murray, Michael Tanowitz,[...]. Nucleic Acids Res 2019
39
100

Design of antisense oligonucleotides stabilized by locked nucleic acids.
Jens Kurreck, Eliza Wyszko, Clemens Gillen, Volker A Erdmann. Nucleic Acids Res 2002
376
100

Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay.
Hans J Gaus, Ruchi Gupta, Alfred E Chappell, Michael E Østergaard, Eric E Swayze, Punit P Seth. Nucleic Acids Res 2019
47
100

Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey.
Scott P Henry, Mark Johnson, Thomas A Zanardi, Robert Fey, Diana Auyeung, Patrick B Lappin, Arthur A Levin. Toxicology 2012
33
100


Kinetics of phosphorothioate oligonucleotide metabolism in biological fluids.
M Gilar, A Belenky, D L Smisek, A Bourque, A S Cohen. Nucleic Acids Res 1997
43
100

Ontogeny and Cross-species Comparison of Pathways Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Neonates (Review): Kidney.
Ruud Bueters, An Bael, Elke Gasthuys, Connie Chen, Michiel F Schreuder, Kendall S Frazier. Drug Metab Dispos 2020
8
100

COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways.
Xue-Hai Liang, Hong Sun, Joshua G Nichols, Nickolas Allen, Shiyu Wang, Timothy A Vickers, Wen Shen, Chih-Wei Hsu, Stanley T Crooke. Nucleic Acids Res 2018
24
100

Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs.
Hongjiang Wu, Walt F Lima, Hong Zhang, Amy Fan, Hong Sun, Stanley T Crooke. J Biol Chem 2004
187
100

Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.
Colton M Miller, Aaron J Donner, Emma E Blank, Andrew W Egger, Brianna M Kellar, Michael E Østergaard, Punit P Seth, Edward N Harris. Nucleic Acids Res 2016
80
100



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.